Treatment of cutaneous in patients with cutaneous T-cell no Aus and lymphoma Dec no Vorinostat Zolinza® 8 Yes 11 None no funding no funding NZ who have 2009 registration March progressive, 2017 persistent or recurrent disease subsequent to prior systemic therapies. The information presented in tables was collated with responses from the hospital survey results and those from the pharmaceutical companies. Medicines Access Programs for which information was also received from the pharmaceutical companies are marked with an asterisk (*) Abbreviations: mNSCLC: metastatic non-small cell lung cancer; mRCC: metastatic renal cell cancer; mBC: metastatic breast cancer; mCRC: metastatic colorectal cancer; pNET: neuroendocrine tumour of pancreatic origin; nNET: neuroendocrine tumour of gastrointestinal or lung origin; SEGA: subependymal giant cell astrocytoma; CLL: chronic lymphocytic leukaemia.
Vorinostat Zolinza® Aus and NZ 8 Yes Treatment of cutaneous in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease subsequent to prior systemic therapies. 11 None Dec 2009 March 2017 no funding no no funding no registration The information presented in tables was collated with responses from the hospital survey results and those from the pharmaceutical companies. Medicines Access Programs for which information was also received from the pharmaceutical companies are marked with an asterisk (*) Abbreviations: mNSCLC: metastatic non-small cell lung cancer; mRCC: metastatic renal cell cancer; mBC: metastatic breast cancer; mCRC: metastatic colorectal cancer; pNET: neuroendocrine tumour of pancreatic origin; nNET: neuroendocrine tumour of gastrointestinal or lung origin; SEGA: subependymal giant cell astrocytoma; CLL: chronic lymphocytic leukaemia.